58 results
8-K
EX-99.1
IDYA
Ideaya Biosciences Inc
20 Feb 24
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023
6:07am
in the IDE397 monotherapy expansion in the priority tumor types, and 2 patients have not yet had a first tumor scan assessment.
Phase 1/2 trial of IDE397 … cancer subject with a first imaging assessment of a PR, which was subsequently confirmed by RECIST 1.1 at the second scan and an 87% reduction of the CA
8-K
EX-99.1
rta9jd6z
7 Nov 23
IDEAYA Biosciences, Inc. Reports Third Quarter 2023
6:01am
424B5
puo3rr
25 Oct 23
Prospectus supplement for primary offering
9:45pm
424B5
hrcpzc1k2p2
24 Oct 23
Prospectus supplement for primary offering
5:26pm
8-K
znx8f8ko8cdk 2m
23 Oct 23
Other Events
8:09am
424B5
y60mew7y4
26 Jun 23
Prospectus supplement for primary offering
5:30pm
424B5
m6kjzehj9bp yls7z
25 Apr 23
Prospectus supplement for primary offering
7:35pm
424B5
w7z7 c12h
24 Apr 23
Prospectus supplement for primary offering
4:53pm
424B5
159 jhd2yl
15 Sep 22
Prospectus supplement for primary offering
5:03pm